Denosumab

Indication

Bone metastasis from solid tumours (NICE TA265)

NICE TA265 - Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours

MHRA Drug Safety Update - Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk

MHRA Drug Safety Update - Denosumab: updated recommendations

MHRA Drug Safety Update - Denosumab (Xgeva▼) for advanced malignancies involving bone: study data show new primary malignancies reported more frequently compared to zoledronate

MHRA Drug Denosumab (Xgeva▼) for giant cell tumour of bone: risk of clinically significant hypercalcaemia following discontinuation

Red

Brand:

Xgeva®

Nice TA:

265

Commissioning responsibility:

CCG

PbR excluded:

No

BNF chapter:

Endocrine system

Background

LMMG is adopting the local decision made prior to April 2013

Recommendation

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

Decisions of Lancashire local decision making groups

BwD	BP	CSR	EL	FW	GP	MB	WL
Red	Red	Red	Red	Red	Red	Amber 1	Red

What do the colours mean?

Last Updated: 01 - May - 2013